For how long should we use symptomatic therapies to treat people with Alzheimer disease?

Canadian Journal of Psychiatry

Volumn 59, Issue 12, 2014, Pages 615-617

  Rockwood, Kenneth ^a,b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Alzheimer disease; Cholinesterase inhibitor; Clinical trial; Dementia; Donepezil; Galantamine; Rivastigmine; Symptoms

Indexed keywords

CHOLINESTERASE INHIBITOR;

ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; CLINICAL PRACTICE; DEMENTIA; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; EDITORIAL; HUMAN; INDIVIDUALIZATION; INTERPERSONAL COMMUNICATION; LONG TERM CARE; MEDICAL SPECIALIST; MEDICATION COMPLIANCE; PATIENT CARE; PATIENT REFERRAL; PHYSICIAN; PRESCRIPTION; PROFESSIONAL PRACTICE; PROFESSIONALISM; TREATMENT DURATION;

ALZHEIMER DISEASE; HUMANS;

EID: 84919434237     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674371405901201     Document Type: Editorial

References (13)

1. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006;(1):CD005593.
2. Gauthier S, Patterson C, Chertkow H, et al. Recommendations of the 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4). Can Geriatr J. 2012;15(4):120-126; and simultaneously in Can J Neurol Sci. 2012; 39(6 Suppl 5):S1-S8.
3. Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Inter n Med. 2008;148(5):379-397.
4. Hogan DB. Long-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer disease. Can J Psychiatry. 2014;59(12):618-623.
5. Maxwell CJ,Stock K,Seitz D,et al., Persistence and adherence with dementia pharmacotherapy: relevance of patient, provider, and system factors, Can J Psychiatry, 2014;59, 12, 624-631.
6. Rockwood K. Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2004;75(5):677-685.
7. Rockwood K, MacKnight C. Assessing the clinical important of statistically significant improvement in anti-dementia drug trials. Neuroepidemiology. 2011;20(2):51-56.
8. Rockwood K, Fay S, Jarrett P, et al. Effect of galantamine on verbal repetition in AD: a secondary analysis of the VISTA trial. Neurology. 2007;68(14):1116-1121.
9. Rockwood K. The importance of measuring executive function when studying the effects of cognition-enhancing agents. Ann Intern Med. 2008;149(5):358-359.
10. Herrmann N, Black SE, Li A, et al. Discontinuing cholinesterase inhibitors: results of a survey of Canadian dementia experts. Int Psychogeriatr. 2011;23(4):539-545.
11. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141(11):1356-1364. 12.
12. US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research. Guidance for industry Alzheimer's disease: developing drugs for the treatment of early stage disease [Internet]. S ilver Spring (MD): US Department of Health and Human Services; 2013 Feb [cited 2014 Jul 3]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM338287.pdf. p 5.
13. . Cummings J, Gould H, Zhong K. Advances in designs for Alzheimer's disease clinical trials. Am J Neurodegener Dis. 2012;1(3):205-216.